Literature DB >> 1201404

Proceedings: A correlation between the response to debrisoquine and the amount of unchanged drug excreted in the urine.

M Angelo, L G Dring, R Lancaster, A Latham, R L Smith.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1201404      PMCID: PMC1666860     

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


× No keyword cloud information.
  1 in total

1.  Quantitative determination of guanethidine and other guanido-containing drugs in biological fluids by gas chromatography with flame ionization detection and multiple ion detection.

Authors:  J H Hengstmann; F C Falkner; J T Watson; J Oates
Journal:  Anal Chem       Date:  1974-01       Impact factor: 6.986

  1 in total
  5 in total

1.  Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.

Authors:  P R Jackson; G T Tucker; M S Lennard; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

2.  3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.

Authors:  Yueying Zhen; Ondrej Slanar; Kristopher W Krausz; Chi Chen; Josef Slavík; Kerry L McPhail; T Mark Zabriskie; Frantisek Perlík; Frank J Gonzalez; Jeffrey R Idle
Journal:  Drug Metab Dispos       Date:  2006-06-16       Impact factor: 3.922

3.  The metabolism of [14C]-debrisoquine in man.

Authors:  J R Idle; A Mahgoub; M M Angelo; L G Dring; R Lancaster; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

4.  Importance of Publishing Adverse Drug Reaction Case Reports: Promoting Public Health and Advancing Pharmacology and Therapeutics.

Authors:  Rashmi R Shah
Journal:  Drug Saf Case Rep       Date:  2017-09-20

5.  Personalized medicine - where do we stand? Pouring some water into wine: a realistic perspective.

Authors:  Ursula Gundert-Remy; Aleksandar Dimovski; Srećko Gajović
Journal:  Croat Med J       Date:  2012-08       Impact factor: 1.351

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.